{"filing": {"accession": "0001493152-26-029325", "cik": "0000946644", "ticker": "AIM", "company_name": "AIM ImmunoTech Inc.", "form_type": "424B3", "filing_type": "424B3", "filing_date": "2026-06-18", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226029325/0001493152-26-029325-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/946644/000149315226029325/0001493152-26-029325-index.htm", "period_of_report": null}, "html_url": "/api/filings/000149315226029325/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 2, "table_type": "text", "caption": null, "header_text": "Page"}, {"table_index": 7, "table_type": "text", "caption": null, "header_text": "\u25cfConducting\n clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic\n cancer."}, {"table_index": 14, "table_type": "text", "caption": null, "header_text": "Issuer:AIM\n ImmunoTech Inc."}, {"table_index": 17, "table_type": "exhibit_index", "caption": null, "header_text": "Use\n of Proceeds:We\n will not receive any proceeds from the sale of the Common Stock by the Selling Stockholders. However, if all of the Warrants and\n Placement Agent Warrants were exercised for cash,"}, {"table_index": 18, "table_type": "text", "caption": null, "header_text": "\u25cf1,173\n shares of our Common Stock issuable upon exercise of outstanding options granted under our 2009 equity incentive plan at a weighted\n average exercise price of $1,669.99 per share; and 23,860 s"}, {"table_index": 19, "table_type": "text", "caption": null, "header_text": "\u25cfno\n exercise of outstanding options or warrants; and"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n price of our Common Stock will likely decrease as a result of the loss of market efficiencies associated with the NYSE American and\n the loss of federal preemption of state securities laws;"}, {"table_index": 28, "table_type": "financial", "caption": null, "header_text": "\u25cfannouncements\n of the results of clinical trials by us or our competitors;"}, {"table_index": 37, "table_type": "text", "caption": null, "header_text": "Shares of Common StockBeneficially Owned Prior to the OfferingNumber of Shares ofCommon Stock BeingShares of Common Stock to beBeneficially Owned After the Offering (2)"}, {"table_index": 41, "table_type": "text", "caption": null, "header_text": "(2)We\n do not know when or in what amounts a selling stockholder may offer shares for sale. The selling stockholders might not sell any\n or might sell all of the shares offered by this prospectus. Bec"}, {"table_index": 44, "table_type": "text", "caption": null, "header_text": "(8)Intracoastal\n Capital LLC: The shares reported under \u201cShares of Common Stock Beneficially Owned Prior to the Offering\u201d consist of 3,076,924\n shares of Common Stock underlying the Class I Warrants h"}, {"table_index": 47, "table_type": "text", "caption": null, "header_text": "\u25cfordinary\n brokerage transactions and transactions in which the broker-dealer solicits purchasers;"}, {"table_index": 56, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfour\n Annual Report onForm 10-Kfor the fiscal year ended December 31, 2025, filed with the SEC on March 27, 2026;"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 46}